ScoreWhy is Medicalgorithmics SA ?
1
Poor Management Efficiency with a low ROE of 0%
- The company has reported losses. Due to this company has reported negative ROE
2
Poor long term growth as Net Sales has grown by an annual rate of -26.13% and Operating profit at 9.04% over the last 5 years
3
The company has declared Negative results for the last 6 consecutive quarters
- INTEREST(HY) At PLN 1.1 MM has Grown at 1,372%
- ROCE(HY) Lowest at -20.93%
- DEBT-EQUITY RATIO (HY) Highest at 25.5 %
4
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 6.06%, its profits have fallen by -23.5%
5
Underperformed the market in the last 1 year
- The stock has generated a return of 6.06% in the last 1 year, much lower than market (Poland WIG) returns of 27.62%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Medicalgorithmics SA for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Medicalgorithmics SA
-100.0%
0.13
40.92%
Poland WIG
27.62%
1.38
19.95%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-26.13%
EBIT Growth (5y)
9.04%
EBIT to Interest (avg)
-17.34
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.03
Sales to Capital Employed (avg)
0.38
Tax Ratio
1.91%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.26%
ROCE (avg)
0.27%
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.85
EV to EBIT
-20.83
EV to EBITDA
-23.65
EV to Capital Employed
4.25
EV to Sales
14.13
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-20.41%
ROE (Latest)
-19.29%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend8What is working for the Company
OPERATING CASH FLOW(Y)
Highest at PLN -5.03 MM
NET PROFIT(HY)
Higher at PLN -6.55 MM
NET SALES(Q)
Highest at PLN 7.19 MM
RAW MATERIAL COST(Y)
Fallen by -45.8% (YoY
-13What is not working for the Company
INTEREST(HY)
At PLN 1.1 MM has Grown at 1,372%
ROCE(HY)
Lowest at -20.93%
DEBT-EQUITY RATIO
(HY)
Highest at 25.5 %
CASH AND EQV(HY)
Lowest at PLN 5.72 MM
Here's what is working for Medicalgorithmics SA
Net Sales
Highest at PLN 7.19 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (PLN MM)
Net Profit
Higher at PLN -6.55 MM
than preceding 12 month period ended Sep 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (PLN MM)
Operating Cash Flow
Highest at PLN -5.03 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (PLN MM)
Raw Material Cost
Fallen by -45.8% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Medicalgorithmics SA
Interest
At PLN 1.1 MM has Grown at 1,372%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (PLN MM)
Debt-Equity Ratio
Highest at 25.5 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Cash and Eqv
Lowest at PLN 5.72 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
